SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Leander Peter)
 

Search: WFRF:(Leander Peter) > (2020-2024) > A novel food-based ...

A novel food-based negative oral contrast agent compared with two conventional oral contrast agents in abdominal CT : a three-arm parallel blinded randomised controlled single-centre trial

Leander, Peter (author)
Perituskliniken AB
Stathis, Georgios (author)
Skåne University Hospital,Lund University
Casal-Dujat, Lucia (author)
Lument AB
show more...
Boman, Karolina (author)
Skåne University Hospital
Adnerhill, Ingvar (author)
Lund University,Lunds universitet,Diagnostisk radiologi, Malmö,Forskargrupper vid Lunds universitet,Radiology Diagnostics, Malmö,Lund University Research Groups,Skåne University Hospital
Marsal, Jan (author)
Lund University,Lunds universitet,Gastro,Forskargrupper vid Lunds universitet,Lund University Research Groups,Skåne University Hospital
Böök, Olof (author)
Lument AB
Fork, Thomas (author)
Lund University,Lunds universitet,Diagnostisk radiologi, Malmö,Forskargrupper vid Lunds universitet,Radiology Diagnostics, Malmö,Lund University Research Groups,Skåne University Hospital,Lument AB
show less...
 (creator_code:org_t)
2022-04-05
2022
English.
In: European Radiology Experimental. - : Springer Science and Business Media LLC. - 2509-9280. ; 6:1
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background: A negative oral contrast agent (OCA) has been long sought for, to better delineate the bowel and visualise surrounding structures. Lumentin® 44 (L44) is a new OCA formulated to fill the entire small bowel. The aim of this study was to compare L44 with positive and neutral conventional OCA in abdominal computed tomography (CT). Methods: Forty-five oncologic patients were randomised to receive either L44 or one of the two comparators (MoviPrep® or diluted Omnipaque®). Abdominal CT examinations with intravenous contrast agent were acquired according to standard protocols. The studies were read independently by two senior radiologists. Results: The mean intraluminal Hounsfield units (HU)-values of regions-of-interest (ROIs) for each subsegment of small bowel and treatment group were -404.0 HU for L44, 166.1 HU for Omnipaque®, and 16.7 HU for MoviPrep® (L44 versus Omnipaque, p < 0.001: L44 versus MoviPrep p < 0.001; Omnipaque versus MoviPrep, p = 0.003). Adverse events, only mild, using L44 were numerically fewer than for using conventional oral contrast agents. Visualisation of abdominal structures beyond the small bowel was similar to the comparators. Conclusions: L44 is a negative OCA with luminal radiodensity at approximately -400 HU creating a unique small bowel appearance on CT scans. The high bowel wall-to-lumen contrast may enable improved visualisation in a range of pathologic conditions. L44 showed a good safety profile and was well accepted by patients studied. Trial registration: EudraCT (2017-002368-42) and in ClinicalTrials.gov (NCT03326518).

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Gastroenterologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)

Keyword

Contrast media
Intestine (small)
Iohexol
MoviPrep
Tomography (x-ray computed)

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view